Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 1021189 phase II dose-finding trial in worsening heart failure with reduced ejection fraction
2013-002287-11Phase 2Completed
- Sponsor
- Bayer
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vericiguat oral suspension in heart failure with reduced ejection fraction (HFrEF) and chronic heart failure (CHF) (5 arms), sponsored by Bayer. Primary endpoint: Change from baseline to week 12 in log-transformed NT-proBNP. Started Sep 2013; status: completed.
02
Drugs
vericiguat oral suspension
03
Conditions
heart failure with reduced ejection fraction (HFrEF)chronic heart failure (CHF)
Beyond the preview
Go deeper on 2013-002287-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002287-11.